Результаты поиска

CAR T-Cell Terrapy Opveiled: Навигация за пределы ССЗ и ИКАНС для решения проблем, связанных с отсроченными последствиями, и оптимизации стратегий управления.

Цимерическая антигенная рецепторная (КАР) T-клетологическая терапия положила начало эпохе преобразований в регулировании рецидивов/отсутствий гематологической гематологии. Кульминацией интенсивных испытаний второго этапа, направленных на борьбу с повторной/охотничьей лимфомой, включая различные подтипы, такие, как диффузная большая лимфома B-клеток, фолликулярная лимфома и лимфома мантичной клетки, а также многочисленные миелома и острая лимфоболическая лейкемия B-клеток, стало одобрение различных продуктов CAR-T-клеток для этих конкретных указаний Администрацией по вопросам продовольствия и н

Совпадение в полном тексте источника
… DD = differential diagnosis; MAS = macrophage activation syndrome; HLH = hemophagocytic lymphohistiocytosis; SBP = systolic blood pressure; IVF = intravenous fluid; FiO2 = fraction of inspired oxygen; G-CSF = granulocyte colony-stimulating factor; ICU = intensive care unit; HF = high flow. … CJ continued to be monitored outpatient twice weekly, requiring granulocyte colony-stimulating factors (G-CSF) and platelet transfusion. In addition, she was initiated on weekly romiplostim for refractory thrombocytopenia. …

Unraveling the mechanisms of bone diseases: targeting dendritic cells in osteoimmunology for internal homeostasis balance.

Bone repair and regeneration is a complex spatiotemporal process recruiting a variety of cell types, which need to precisely mediated for effective healing post-damage. The concept of osteoimmunology emphasizes the extensive and intricate crosstalk between the bone and the immune system. Despite the significant advancements in understanding osteoimmunology, the precise role of dendritic cells (DCs) in this field remains under investigation. As key antigen-presenting cells, DCs are critical in orchestrating adaptive immune responses and maintaining tissue homeostasis. Recent researches have fur

Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure.

Background and Objectives: Autologous stem cell transplantation (ASCT) remains the standard of care for relapsed or refractory Hodgkin lymphoma (R/R HL), and an increasing proportion of patients receive programmed cell death protein 1 (PD-1) inhibitors prior to transplantation. Engraftment syndrome (ES) is a noninfectious inflammatory complication classically associated with neutrophil recovery; however, early peri-transplant inflammatory manifestations remain poorly characterized and may mimic infectious complications. We aimed to evaluate peri-transplant inflammatory events after ASCT, with

Совпадение в полном тексте источника
… In addition, the observed symptoms may reflect noninfectious inflammatory processes unrelated to classical ES, including drug-related toxicity (e.g., conditioning regimen-associated mucosal or pulmonary injury), granulocyte colony-stimulating factor (G-CSF)-associated cytokine-mediated inflammatory reactions … Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI) Transplant. Cell. …

Immunologic tumor microenvironment modulators for turning cold tumors hot.

Tumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot tumors, characterized by heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), stand in stark contrast to cold tumors, which lack immune infiltration and remain resistant to therapy. To overcome immune evasion mechanisms employed by tumor cells, novel immunologic modulators have emerged, particularly ICIs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein

Noninfectious pulmonary complications of haematopoietic stem cell transplantation.

Haematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and nonmalignant conditions. Pulmonary complications, both infectious and noninfectious, are a major cause of morbidity and mortality in patients who undergo HSCT. Recent advances in prophylaxis and treatment of infectious complications has increased the significance of noninfectious pulmonary conditions. Acute lung injury associated with idiopathic pneumonia syndrome remains a major acute complication with high morbidity and mortality. On the other hand, bronchiolitis obliterans syndrome is

The Impact of an Embedded Oncology Pharmacist in an Outpatient Oncology Center in the Treatment of Hematologic Malignancies.

BackgroundThe growing demand for clinicians in the ambulatory oncology setting to reduce fragmentation of care and improve patient outcomes represents a need for oncology pharmacists as advanced practitioners in the provision of direct patient-centered care. These provisions can include supportive care management, drug-drug interaction evaluation, and selection of appropriate chemotherapy regimens to reduce physician workload in a cost-effective manner, while increasing physician and patient satisfaction. However, robust data are currently lacking to support the impact of pharmacists in the am

Совпадение в полном тексте источника
… Pharmacist supportive care interventions were further divided into nine subcategories ( Figure 1 ): gastrointestinal (n = 46), anti-infective (n = 37), other (n = 30), immunization (n = 28), tumor lysis syndrome (n = 25), cancer-associated venous thromboembolism (n = 10), granulocyte colony-stimulating … SC = supportive care; OC = order clarification; NV = nausea and vomiting; G-CSF = granulocyte colony-stimulating factor; CA VTE = cancer-associated venous thromboembolism; TLS = tumor lysis syndrome. a diarrhea, constipation, mucositis, heartburn SC: NV | SC: GI a | SC: Anti-infective | SC: G-CSF related …

Monitoring NK cell activity in patients with hematological malignancies.

Natural killer (NK) cells are lymphocytes of the innate immune system that can recognize and kill various types of malignant cells. Monitoring the activity of peripheral NK cells in patients affected by hematological malignancies may provide prognostic information or unveil ongoing tumor-specific immune responses. Moreover, further insights into the biology of NK cells might also promote the development of novel strategies for stimulating their anticancer activity. Here, we review the main methods to monitor phenotypic and functional NK cell properties in cancer patients, focusing on individua

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.

ObjectiveValue frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS).MethodsHere we present the results of the first feasibility testing of the ESMO-MCBS v1.1 for haematological malignancies based on the grading of 80 contemporary studies for acute leukaemia, chronic leukaemia, lymphoma, myeloma and myelodysplastic syndromes. Th

Совпадение в полном тексте источника
… Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the eastern cooperative Oncology Group (E1996). Blood 2009;114:2393–400. 10.1182/blood-2009-03-211797 113. … Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321–7. 10.1182/blood-2003-07-2252 114. Platzbecker U, Symeonidis A, Oliva EN, et al. …

Факторы риска, выходящие за рамки воздействия химиотерапии на вторичные миелоидные неоплазмы после рака гематологов: исследование на основе СЭЭУ.

UNLABELLED. По мере того, как показатели выживаемости лимфоидных магнатов продолжают улучшаться, для выживших людей все большее значение приобретает понимание поздних последствий после лечения, таких, как вторичные миелоидные новообразования (SMN). В этом крупномасштабном исследовании населения (SEER-Medicare) были изучены факторы риска и кумулятивная распространенность SMN у пациентов с диагнозом диффузной большой лимфомы B-клеток (DLBCL), фолликулярной лимфомы (FL) и множественной миеломы между 2000 и 2011, с последующими мерами 2015. Пациенты с ПЛ постоянно увеличивают совокупное число НРМ

Совпадение в полном тексте источника
… Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy . J Natl Cancer Inst 2007 ; 99 : 196 – 205 . 17284714 10.1093/jnci/djk028 14. … Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review . J Clin Oncol 2010 ; 28 : 2914 – 24 . 20385991 10.1200/JCO.2009.25.8723 15. Lyman GH , Dale DC . …

Radiation induced oral mucositis.

PATIENTS RECEIVING RADIOTHERAPY OR CHEMOTHERAPY WILL RECEIVE SOME DEGREE OF ORAL MUCOSITIS THE INCIDENCE OF ORAL MUCOSITIS WAS ESPECIALLY HIGH IN PATIENTS: (i) With primary tumors in the oral cavity, oropharynx, or nasopharynx; (ii) who also received concomitant chemotherapy; (iii) who received a total dose over 5,000 cGy; and (iv) who were treated with altered fractionation radiation schedules. Radiation-induced oral mucositis affects the quality of life of the patients and the family concerned. The present day management of oral mucositis is mostly palliative and or supportive care. The newe

Эффективность бортезомиба в сочетании с гипер-CVAD у взрослых с рецидивом острой лимфоболической лейкемии или положительными измеримыми остаточными заболеваниями; воздействие бортезомиба в лейкемии.

Несмотря на прогресс, достигнутый в лечении острой лимфоболической лейкемии (ОЛЛ), рецидив остается наиболее серьезной проблемой в деле улучшения прогнозирования. Оценка измеримых остаточных заболеваний (MRD) может спрогнозировать рецидив костного мозга на основе позитивности MRD. Поскольку доступ к инновационным методам лечения по-прежнему ограничен из-за высоких затрат, химиотерапия является широко используемым вариантом лечения. Об эффективности сочетания бортезомби и Hyper-CVAD сообщалось у пациентов с множественной миеломой; однако его эффективность еще не была подтверждена у пациентов, и

Совпадение в полном тексте источника
… Toxicity and outcome All 43 patients who received treatment experienced grade 4 hematological toxicity requiring granulocyte colony-stimulating factor and transfusion support. Febrile neutropenia occurred in 62.8% (n = 27) patients, necessitating broad-spectrum antibiotic treatment. … Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma. 1997;25(5–6):579–83. Available from: 10.3109/10428199709039047 24. Yavuz S, Paydas S, Disel U, Sahin B. …

Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer.

Prostate cancer (PCa) is the second-most common cancer in men worldwide and treatment options for patients with advanced or aggressive prostate cancer or recurrent disease continue to be of limited success and are rarely curative. Despite immune checkpoint blockade (ICB) efficacy in some melanoma, lung, kidney and breast cancers, immunotherapy efforts have been remarkably unsuccessful in PCa. One hypothesis behind this lack of efficacy is the generation of a distinctly immunosuppressive prostate tumor microenvironment (TME) by regulatory T cells, MDSCs, and type 2 macrophages which have been i

Role of T cells and cytokines in the pathogenesis of rheumatoid arthritis.

Rheumatoid arthritis (RA) is a long-term autoimmune disease. It causes persistent joint inflammation, aberrant tissue growth, and progressive joint deterioration. T cells have a key role in the onset of RA. They identify and trigger other immune cells, and produce inflammatory signals such as interleukin-6 (IL-6), interleukin-17 (IL-17), and tumor necrosis factor-α (TNF-α). Prolonged inflammation and tissue damage are caused by an imbalance between regulatory T cells (Tregs) and pro-inflammatory T helper 17 (Th17) cells. Additionally, the condition is exacerbated by uncontrolled cytokine netwo

T1 Mapping in Cardiovascular Magnetic Resonance-A Marker of Diffuse Myocardial Fibrosis in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Introduction: Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of cardiovascular diseases. In our study, we aimed to find subclinical changes in myocardial tissue after HSCT with the help of cardiovascular magnetic resonance (CMR) tissue imaging techniques. Methods: The data of 44 patients undergoing autologous and allogeneic HSCT in the Hospital of Lithuanian University of Health Sciences Kaunas Clinics from October 2021 to February 2023 were analyzed. Bioethics approval for the prospective study was obtained (No BE-2-96). CMR was performed two times: before enr

Совпадение в полном тексте источника
… HSC with properties of long-term hematopoietic reconstitution can be identified from bone marrow or chemotherapy and/or granulocyte colony-stimulating factors (G-CSF) mobilized peripheral blood or umbilical cord blood [ 5 , 6 , 7 ]. … Hematopoietic stem cell harvesting for autologous HSCT was performed with chemotherapy and granulocyte colony stimulating factors (G-CSF)—chemo-mobilization. …

Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Hematopoietic stem cells (HSCs) are a rare subset of bone marrow cells that usually exist in a quiescent state, only entering the cell cycle to replenish the blood compartment, thereby limiting the potential for errors in replication. Inflammatory signals that are released in response to environmental stressors, such as infection, trigger active cycling of HSCs. These inflammatory signals can also directly induce HSCs to release cytokines into the bone marrow environment, promoting myeloid differentiation. After stress myelopoiesis is triggered, HSCs require intracellular signaling programs to

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent adverse events compromising quality of life (QoL) in patients undergoing autologous stem cell transplantation (ASCT). However, CINV prophylaxis is still lacking uniformity for high-dose melphalan (HDM), which is used to condition patients with multiple myeloma (MM). Netupitant/palonosetron (NEPA) is administered with dexamethasone (DEXA) for CINV prevention in several chemotherapy regimens. Our study aims to assess the efficacy of NEPA, without DEXA, in preventing CINV in 106 adult patients with MM receiving HDM and AS

Совпадение в полном тексте источника
… High-dose cyclophosphamide (2–4 g/m 2 ) plus granulocyte colony-stimulating factor was used to mobilize peripheral blood stem cells. … Granulocyte colony-stimulating factor (pegfilgrastim) was administered on day + 1. …

Sepsis in patients with haematological versus solid cancer: a retrospective cohort study.

ObjectivesThis study aims to examine the outcome of haematological and patients with solid cancer presenting with sepsis to the emergency department (ED).DesignSingle-centred, retrospective cohort study. Setting conducted at an academic emergency department of a tertiary hospital.ParticipantsAll patients >18 years of age admitted with sepsis were included.InterventionsPatients were stratified into two groups: haematological and solid malignancy.Primary and secondary outcomeThe primary outcome of the study was in-hospital mortality. Secondary outcomes included intensive care unit (ICU) mortalit

Antineoplastics : Lack of efficacy and infusion reaction: case report

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy.

Purpose of reviewAcute myeloid leukemia (AML) in children remains a challenging disease to cure with suboptimal outcomes particularly when compared to the more common lymphoid leukemias. Recent advances in the genetic characterization of AML have enhanced understanding of individualized patient risk, which has also led to the development of new therapeutic strategies. Here, we review key cytogenetic and molecular features of pediatric AML and how new therapies are being used to improve outcomes.Recent findingsRecent studies have revealed an increasing number of mutations, including WT1, CBFA2T

Эффективность и безопасность селелексора в сочетании с VRD в недавно диагностированном миеломе с EMD: фазы 2 суд.

Вышеупомянутая болезнь (ЭМД) в диагностике дает плохой прогноз в недавно диагностированном миеломе (НДММ). Этот многоцентровый, открытый знак, односторонний, фазы 2, инициированный следователем суд оценил селинксор в сочетании с бортезомидом, линалидомидом и дексаметазоном (СВОД) в NDMM вместе с EMD. Между 17 октябрь 2022 и 27 ноябрь 2025, 30 - пациенты были зачислены в школу; 29 Лечащие пациенты сформировали модифицированное намерение к лечению (МИТТ) и безопасные группы населения (средний возраст, 60 США). Включая вводные данные four 28-day Циклы СВРД с установленными протоколами консолидаци

Совпадение в полном тексте источника
… To emphasize, 3 patients experienced grade 3/4 neutropenia, all of whom were managed with granulocyte colony-stimulating factor (G-CSF) for secondary prophylaxis at the investigator’s discretion. … colony-stimulating factor) dose in cycle 3. …